Epigenetic drug discovery is exploding across the industry

And EpiCongress will place you right at the heart of the action…

With more epigenetics focused companies than anywhere else, the epicenter for epigenetic drug developers is returning to Boston this July 23 - 26.
 
The meeting has been designed in collaboration with thought leaders at GSK, EpiZyme, Constellation, Pfizer, Genentech, Celgene, Abbvie, Gilead, Acetylon, and many more. EpiCongress will not only help you to understand the basic mechanisms behind genome regulation and chromatin function. It will also address the most pressing clinical considerations to ensure the success of current and future candidates.

Hear from 50 expert speakers from across pharma, biotechs and research institutes presenting their most promising data. Capture the last 12 months of progress by hearing how epigenetic candidates have been performing across the board. And access the translational science with the potential to transform your drug discovery.

New companies joining us this year include...


Personalize your agenda

With over 30 industry presentations and pharma packed discussions, covering everything from target discovery to patient selection, choose the presentations which are most applicable to your research. Take the time to explore what’s on offer throughout the streams to build your personalized 2 day itinerary.

Attend the FUNDAMENTAL EPIGENETICS stream to:

  • Learn about genome regulation to explore the therapeutic opportunities in altered epigenomic states
  • Explore the biology and pharmacological properties behind selected HMT and demethylases compounds 
  • Get to grips with heterogeneity in neuropsychiatric disorders to see  how it can impact your therapeutic strategies

Get the latest from the EPIGENTIC INNOVATIONS stream:

  • Get an insight into unpublished data from the industry’s exciting EZH2 programs
  • Understand the chemistry behind LSD1 histone methyltransferases and demethylases to develop potent and specific small molecule inhibitors
  • Improve your target validation by identifying which inhibitors are ticking all the boxes for pharma

Take part in the discussions during the EPIGENETICS IN THE CLINIC stream to:

  • Choose the most effective biomarker strategies for your program and discuss what clinical biomarkers will look like for novel epigenetic drugs
  • Discover how companies are currently selecting their PK/ PD endpoints for early clinical trials
  • Learn from those who have achieved successful patient selection so far in phase 1 and 2 

Don’t miss the interactive workshops

Make the most out of your time at EpiCongress by taking part in the pre and post conference workshops. These sessions offer you the chance to bring your own questions to the table to discuss solutions with your peers in a more open and informal format. Choose from the selection of individual workshops or attend all four... 

Pre-conference workshops:

A: Epigenomics Data Management and Visualization Strategies
Led by Charles Epstein, Program Manager, The Broad Institute of Harvard & MIT 

B: Bridging Epigenetic Mechanisms and Stem Cell Biology
Led by Zhong Wang, Assistant Professor of Medicine, Massachusetts General Hospital

Post-conference workshops:

C: Translating Epigenetic Regulation to Clinical Candidates
Led by Daniel Vitt, CSO, 4SC & Hella Kohlhof, Manager, Translation Pharmacology, 4SC

D: Pathway-based Application of Epigenetic Drugs to Optimize Clinical Safety and Efficacy
Led by: Yogen Saunthararajah, Associate Professor, Cleveland Clinic 

Who should attend?

  • Epigenetic drug developers looking to progress epigenetic drugs into the clinic and meet business leaders
  • Pharma companies with a strong interest in epigenetic drug development
  • Technology specialists seeking to highlight novel platforms, assays and equipment
  • Business development professionals assessing pipeline investment opportunities
  • Scientists and academics working in medicinal chemistry and the wider epigenetic spectrum

Download Brochure | Prices & Packages | Register Now

Download the brochure for...

Led by: Daniel Vitt, CSO, 4SC & Hella Kohlhof, Manager, Translation Pharmacology, 4SC